The University of Queensland (UQ) has announced a wireless neuro-stimulator to treat neurological disorders such as Parkinson’s, chronic depression and other psychiatric conditions.
The university’s Queensland Brain Institute (QBI) collaborated with Neurosciences Queensland and Abbott Neuromodulation to develop the remote care platform.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It allows patients to access treatment from anywhere in the world.
Using the new integrated digital platform, clinicians will be able to monitor patients remotely, treat symptoms in real-time and adjust the device for treatment.
The wireless platform would help support data-driven clinical decisions and also allow more personalised treatment.
Queensland Brain Institute professor Peter Silburn said: “We have shown that it is possible to minimise disruption to patients’ and carers’ lifestyles by increasing accessibility to the service, saving time and money.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“There are no cures for many of these conditions, which often require life-long treatment and care, so for those people the device would be a game-changer.”
Launched last October in Australia, the digital health platform has now received CE-Mark as well as US Food and Drug Administration (FDA) approval.
UQ noted that the research team commenced working on the new platform prior to the Covid-19 pandemic, which elevated the need for remote care platforms, mainly for the treatment of older people and patients in remote areas.
They also stated that the new technology can be adapted for other conditions in the future.
